Alkermes (ALKS) Q2 2026 earnings review
Avadel Integration Fuels Revenue Jump; Debt and CVR Crush GAAP Income
Alkermes delivered an Accelerating top-line performance, with Q2 revenue jumping 27% YoY to $496.0 million. This breakout breaks a stable ~$390M quarterly run-rate and is entirely driven by the integration of LUMRYZ, which contributed $96.6 million. Adjusted EBITDA expanded 10% to $139.2 million. However, the GAAP bottom line tells a radically different story: Net Income plummeted from $87.1M a year ago to just $0.5M. The severe GAAP contraction is due to heavy Avadel transaction costs, $25.9M in quarterly interest expense, and a $26.4M contingent consideration charge triggered by positive LUMRYZ clinical data. The company also announced a major leadership transition, with COO Blair Jackson succeeding Richard Pops as CEO.
🐂 Bull Case
The Avadel acquisition is immediately accretive to the top line, with LUMRYZ generating $96.6 million in Q2. Positive Phase 3 data for idiopathic hypersomnia opens a path to label expansion in an underdeveloped market.
LYBALVI net sales increased 12% YoY, supported by an 18% increase in total prescriptions, demonstrating effective commercial execution in the psychiatry franchise.
🐻 Bear Case
ARISTADA revenue fell to $96.7M from $101.3M a year ago, despite a $4M gross-to-net benefit. VIVITROL growth remains flat.
The $1.525 billion term loan taken for Avadel has resulted in $25.9M of interest expense this quarter alone. The GAAP net loss guidance for FY26 worsened to $95-$115 million.
⚖️ Verdict: ⚪
Neutral. The strategic pivot toward sleep medicine (LUMRYZ) and the orexin pipeline is bearing immediate revenue fruit. However, the massive debt burden, ARISTADA's deceleration, and widening GAAP losses introduce significant intermediate-term friction.
Key Themes
LUMRYZ Transforms the Top Line
LUMRYZ was the definitive growth engine this quarter, generating $96.6 million (including a ~$7M inventory benefit). The recent positive topline results for its Phase 3 study in idiopathic hypersomnia (IH) triggered a $26.4 million CVR milestone adjustment. This validates the Avadel acquisition strategy, establishing Alkermes' commercial footprint in sleep medicine well ahead of the eventual alixorexton launch.
LYBALVI Execution Remains Strong
LYBALVI revenues achieved $94.0 million, representing a 12% YoY increase. This growth is underpinned by an 18% increase in total prescriptions, demonstrating that the expanded psychiatry sales force is successfully driving underlying demand and expanding the prescriber base.
Orexin Pipeline Advancing Rapidly
Alkermes' long-term valuation hinges on its orexin 2 receptor agonist portfolio. Management confirmed that the first ADHD data for ALKS 7290 is expected in the coming months, while topline results from the alixorexton Phase 2 idiopathic hypersomnia study are slated for year-end. This methodical de-risking positions the company to expand beyond narcolepsy.
ARISTADA Revenue Reversing
A clear point of concern is ARISTADA. The product saw revenues drop to $96.7 million from $101.3 million a year ago. Even more concerning, this deceleration occurred despite the company recording a ~$4 million benefit related to gross-to-net favorability. The underlying volume contraction contradicts the positive narrative surrounding the expanded psychiatry sales force.
Macro Impact: High Interest Rates Bite into Leveraged Balance Sheet
The company's new $1.525 billion term loan, taken to fund the Avadel acquisition, has materially altered Alkermes' risk profile in a high-interest-rate environment. Net interest expense for Q2 was $25.9 million, dragging GAAP Net Income to near zero ($0.5M). Management is projecting $75-$85 million in full-year net interest expense, requiring sustained high cash flow from operations to service.
Gross-to-Net (GTN) Adjustments Obscuring Core Growth
Similar to prior quarters, Q2 results were buoyed by one-time gross-to-net favorability. ARISTADA and VIVITROL each benefited by approximately $4 million. Investors must monitor these adjustments carefully, as management previously indicated that LYBALVI's GTN deductions are expected to widen into the mid-30s.
CEO Succession Plan Finalized
Long-time CEO Richard Pops will transition to Chairman on August 1, handing the reins to current COO Blair Jackson. This transition occurs as the company pivots sharply from psychiatry to sleep medicine, signaling a focus on operational execution for the critical alixorexton clinical trials and LUMRYZ commercial integration.
Other KPIs
Up sequentially from $538.2 million at the end of Q1 2026. This sequential build reflects strong cash generation from the newly integrated operations, which will be essential for paying down the $1.525 billion term loan and funding the expansive orexin R&D pipeline.
Stable YoY. VUMERITY generated $30.6 million, while the XEPLION/INVEGA family provided $27.5 million. This segment continues to provide a steady, high-margin cash stream to supplement proprietary product sales.
Guidance
Stable. The company reiterated its previous top-line guidance. The midpoint ($1,785M) implies a massive 21% YoY acceleration over FY25's ~$1.48B, almost entirely driven by the inorganic addition of LUMRYZ.
Stable. The guidance range was reiterated. This covers the post-acquisition period (Feb 12 - Dec 31). Achieving this target requires maintaining the strong $90M+ quarterly run-rate seen in Q2.
Decelerating/Worsening. The company lowered its GAAP net loss guidance from the previous range of $(70)-$(90) million. The $25 million deterioration is directly attributable to the non-cash change in fair value of contingent consideration following the positive LUMRYZ Phase 3 trial.
Stable. Reiterated from prior guidance. The midpoint ($390M) represents a slight step down from FY25's $394.0M, reflecting the heavy integration costs and R&D ramp for the orexin pipeline, despite the higher revenue base.
Key Questions
ARISTADA Underperformance
ARISTADA sales declined YoY to $96.7 million despite a $4 million gross-to-net benefit. Is the expanded psychiatry sales force losing traction with this product while prioritizing LYBALVI, or are there new competitive pressures emerging?
LUMRYZ Underlying Demand vs. Inventory
LUMRYZ posted a strong $96.6 million, but this included a $7 million inventory benefit. How much of the sequential growth was driven by net new patient starts versus channel stocking, and what is the expected normalized run-rate for Q3?
Debt Reduction Timeline
With $25.9 million in interest expense this quarter and an updated GAAP Net Loss guidance of up to $115 million, what is the specific target trajectory for paying down the $1.525 billion term loan over the next 12-18 months?
ALKS 7290 Data Expectations
As we approach the initial ADHD data readout for ALKS 7290, what specific efficacy (AISRS scale) and tolerability benchmarks do you need to see to aggressively advance the molecule into a larger Phase 2b/3?